Navigation Links
Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
Date:8/3/2009

PALO ALTO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that the positive results from a Phase 1 multicenter, dose escalation study of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with Myelodysplastic Syndrome (MDS) have been published in a leading peer reviewed journal, Blood, 25 June 2009; Vol. 113, No. 26, pp. 6533-6540. Positive results from a separate Phase 1-2a study in MDS patients involving an intravenous formulation of TELINTRA were published earlier in the Journal of Hematology and Oncology,13 May 2009; Vol. 2, No.20, pp. 20-32. The findings reported from these studies support the further development of TELINTRA. Phase 2 studies are ongoing in MDS (enrollment completion expected by year end), and Severe Chronic Idiopathic Neutropenia. Reprints of both publications are available from Telik.

Background on MDS and TELINTRA

MDS is a heterogeneous group of blood stem cell disorders of increasing incidence. MDS is characterized by ineffective blood cell production involving one or more of the red cell, white cell or platelet lineages and with MDS patients having a variable risk of progression to leukemia. There remains a need for effective, well tolerated therapies for MDS having novel mechanisms of action. TELINTRA has a novel mechanism of action that inhibits a target enzyme called glutathione S- transferase P1-1 which in turn facilitates the activation of JNK kinase, a key regulator of cellular growth and differentiation of blood. TELINTRA has been shown to stimulate normal multilineage differentiation of blood stem cell precursors and induce cancer cell death in human leukemia cell lines. Additional information on TELINTRA is available at www.telik.com.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA((R)), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP((R)), which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Presentation at ASCO Annual Meeting
2. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
3. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
4. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
5. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
6. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
7. Cryo-Cell Announces Celle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.
8. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
9. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
10. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
11. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Research and Markets has announced the addition ... Demand Forecast to 2022" report to their offering. ... , , The ... and it is expected to grow at a CAGR of 5.5% during ... faster growth during the forecast period, a CAGR of 8.8% in the ...
(Date:12/2/2016)... , Dec. 2, 2016 Quantum Radiology,s Mobile ... expert radiologist interpretation directly to women at the workplace, ... corporations, such as Delta Air Lines and SunTrust Bank, ... as a component of wellness initiatives. "I ... SunTrust. It enables them to have a mammogram without ...
(Date:12/2/2016)... 2016 In the first ever attempt to ... derived from C. sativa, the Hebrew University in Jerusalem, ... Federico II , the Universita` del Piemonte Orientale and ... integrated and unified inventory of phytocannabinoids of different botanical ... the remarkable chemical and structural diversity of phytocannabinoids. As ...
Breaking Medicine Technology:
(Date:12/2/2016)... CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, Doctors ... basis to help personal injury victims find high quality medical care. When the company ... Angeles area. Fast forward to present day and the now ten-page directory features a ...
(Date:12/2/2016)... ... 02, 2016 , ... Center for Autism and Related Disorders (CARD) Portland today ... spectrum disorder (ASD) and other developmental disabilities. The group, which is being launched with ... caregivers the opportunity to share stories and advice, seek help, and continue their education ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... Wilmington, Delaware (PRWEB) , ... December 02, 2016 ... ... has released a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite ... from sample entry through labeling, storing, shipping and disposal. The new version is ...
(Date:12/2/2016)... ... ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology that ... technology on the market can deliver all that rejiva can. , “Rejiva promotes relaxation ... health than the usual heart rate and steps taken”, adds Evens Augustin, CEO of ...
Breaking Medicine News(10 mins):